



health

Department:
Health
REPUBLIC OF SOUTH AFRICA

Private Bag X828, PRETORIA, 0001, Civitas Building, Pretoria

Reference: EDP022019/04

NOTICE: IPRATROPIUM BROMIDE USE AND PROCUREMENT

Ipratropium bromide inhalation is only recommended as add-on therapy for severe acute exacerbations of asthma and chronic obstructive pulmonary disease in adults, in the Primary Health Care and Standard Treatment Guidelines (STGs) Essential Medicines List (EML), where nebulisation with ipratropium bromide unit dose vials may not be possible.

The recommendations in the PHC STGs and EML, 2018 edition are as follows:

Indication: Primary Health Care Level	Current recommendation in the STGs and EML
17.1.1 Acute Asthma and Acute exacerbations of COPD <i>- Adults with severe attacks while awaiting referral</i>	If poor response after first salbutamol nebulisation/inhalation: <ul style="list-style-type: none">Ipratropium bromide solution, 0.5 mg nebulised, 2 mL (0.5 mg) added to salbutamol solution every 20–30 minutes for 3 doses depending on clinical response. OR <ul style="list-style-type: none">Ipratropium bromide, inhalation using MDI, 80–160 mcg (2–4 puffs), using a spacer every 20–30 minutes as needed for up to 3 hours.

Note: Adult patients with inadequate control of symptoms, requiring continuous use of salbutamol or ipratropium inhalation/nebulisation should be referred to secondary level of care for further management.

Other indications for ipratropium in the STGs and EML involve the use of unit dose vials for nebulisation at primary health care or secondary level.

Availability and Procurement

The awarded quantities of ipratropium bromide metered dose inhaler 40mcg have been exceeded, and thus the supplier has informed the National Department of Health that they are unable to continue supply and have stopped accepting orders (Attached letter dated 19 October 2018). Cancellation of this contract is being attended to by the National Treasury.

A quotation of an alternative item Ipratropium Bromide 20mcg, 200 doses, Inhaler 10ml (Atrovent 20HFA MDI 10ml) has been received from Boehringer Ingelheim (Pty) Ltd and Provinces are requested to procure using the attached quotation.

Comments and queries may be submitted to:

Availability and access queries:

Mr. Jacobus Stokes

Tel: 012 395 8464

Email: Jacobus.Stokes@health.gov.za

Clinical queries:

Essential Drugs Programme

Tel: 012 395 8287/8224

Email: SAEDP@health.gov.za

Kind regards


MS K JAMALOODIEN
DIRECTOR: AFFORDABLE MEDICINES
DATE: 11/2/2019

To: Ms K Jamaloodien
Director: Affordable Medicines
National Department of Health

From: Cipla Medpro South Africa (Pty) Ltd

Tel: 021 914 0520

Date: 19 October 2018

Re: Discontinuation of supply of Item 62: Ipratropium metered dose inhaler to HP07-2017DAI (Ipvent 40 HFA)

Dear Madam

Item 62: Ipratropium metered dose inhaler, 40mcg per actuation, complete, 200 metered doses to HP07-2017DAI, (NSN 180001335), Cipla Medpro SA (Pty) Ltd was awarded 100% of the contract for this aforementioned item and effectively 196 059 units. To date in the current HP07-2017DAI contract, Cipla Medpro South Africa (Pty) Ltd have already supplied 271 693 units to the Procuring Authorities, which is 139% of its contract obligation.


Due to a long-term manufacturing issue experienced, as well as the nature of the problem, we will be out of stock indefinitely and we will regrettably not be able to accept additional orders and supply any further units on this product for the duration of the current contract.

We therefore wish to inform National Department of Health that Cipla Medpro South Africa (Pty) Ltd by virtue of exceeding the supply of its allocated quantity significantly, has fulfilled its contractual obligation in the supply of Item 62: Ipratropium metered dose inhaler, 40mcg per actuation, complete, 200 metered doses for HP07-2017DAI, and will discontinue the supply of the item.

Therefore, we respectfully request the Department of Health to inform the Procuring Authorities, by way of formal instruction or addendum, to no longer place orders for Item 62: Ipratropium metered dose inhaler, 40mcg per actuation, complete, 200 metered doses to HP07-2017DAI, (NSN 180001335), with Cipla Medpro SA (Pty) Ltd.

Please do not hesitate to contact me directly and I will remain in contact with the National Department of Health via the established channels.

Regards



Willem Maritz
Director - State Business.
Cell: 082 887 4926
e-mail: willem.maritz@cipla.com